Neuronal nicotinic acetylcholine receptor (alpha-3, alpha-4, beta-2) (nAChR (alpha3, alpha4, beta2))

Neuronal nicotinic acetylcholine receptors (nAChRs) containing alpha-3, alpha-4, and/or beta-2 subunits are pentameric ligand-gated ion channels that mediate fast excitatory neurotransmission and modulate the release of other neurotransmitters in the central and peripheral nervous systems [1, 7]. The alpha-4/beta-2 subtype is the most prevalent heteromeric nAChR in the mammalian brain, where it exhibits high affinity for nicotine and plays a critical role in cognitive functions, reward pathways, and the development of nicotine addiction [6, 9, 18]. Receptors containing the alpha-3 subunit, often in combination with beta-2 or beta-4, are prominently expressed in autonomic ganglia and certain brain regions like the hippocampus and medial habenula, contributing to autonomic regulation and synaptic plasticity [2, 4, 13]. These receptors are significant therapeutic targets; for instance, alpha-4/beta-2 partial agonists like varenicline are used for smoking cessation by reducing nicotine cravings and withdrawal symptoms [1, 11]. Furthermore, these nAChR subtypes are being investigated for their potential in treating neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia, due to their ability to enhance cholinergic signaling and provide neuroprotection [1, 17, 21]. Drugs targeting these receptors often act as orthosteric agonists or allosteric modulators, though selectivity remains a challenge due to the structural similarity between subunits and the potential for peripheral side effects [5, 15].

Other names

alpha4beta2 nAChRalpha3beta2 nAChRalpha3alpha4beta2 nAChRHigh-affinity nicotine receptorNeuronal nicotinic receptorCHRNA3/CHRNA4/CHRNB2-containing nicotinic receptor

Ligand-gated ion channel activation; agonist binding at subunit interfaces induces a conformational change that opens a cation-selective pore, leading to neuronal depolarization and modulation of neurotransmitter release [1, 3, 6].